Velesco Pharma Acquires New R&D and cGMP Analytical Lab

Published on: 

Pharmaceutical Technology's In the Lab eNewsletter

In the Lab eNewsletter, Pharmaceutical Technology\'s In the Lab eNewsletter-11-07-2018, Volume 13, Issue 11

he acquisition expands the company’s formulation and analytical R&D services.

Velesco Pharm, a development and clinical manufacturing company, has acquired a new facility in Wixom, MI, that expands and enhances its formulation and analytical R&D capabilities, the company announced on Oct. 23, 2018.

The acquisition and fit-out of the new facility double the company’s formulation and analytical laboratory space. The increase in capacity expands its research and cGMP services, including formulation development, analytical method development/validation, release and stability testing, and cGMP clinical manufacturing. The move to the expanded facility will occur before the end of 2018.

“Our new laboratory is impressively designed and equipped, and we will be increasing our scientific team such that we can meet our clients’ growing demand for pharmaceutical formulation and analytical services,” said Dave Barnes, PhD, CEO at Velesco, in a company press release.


Source: Velesco Pharm